Business Context and Reporting Period
Cocrystal Pharma, Inc., a Delaware corporation focused on the development of novel medicines for human viral diseases, filed this Form 8-K on April 30, 2018. The report details the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 4,210,527 shares of common stock.
- Public Offering Price: $1.90 per share.
- Over-Allotment Option: Underwriter granted an option to purchase up to 631,578 additional shares within 45 days.
- Gross Proceeds: Approximately $8.0 million (excluding underwriting discounts, commissions, and offering expenses).
- Use of Proceeds: General corporate purposes and continued drug development.
- Warrant Issuance: Underwriter to receive a warrant for 84,211 shares at an exercise price of $2.09 per share (110% of public price).
- Director Participation: Two directors indicated intent to purchase up to $1,000,000 of shares.
Material Changes and Agreements
The primary material change is the execution of an underwriting agreement with A.G.P./Alliance Global Partners. The agreement includes a 90-day lock-up provision preventing the Company, its officers, and directors from selling shares without underwriter consent. The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Closing Date: Expected on or about May 3, 2018, subject to customary conditions.
- Warrant Terms: The warrant becomes exercisable 180 days after closing and expires four years thereafter.
- Financial Credits: The Company will receive a $40,000 credit at closing, plus an additional $16,625 if the over-allotment option is exercised.
- Risk Factors: The filing notes that representations and warranties are subject to limitations and confidential disclosures exchanged between parties.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm whether the underwriter exercises the 631,578 share over-allotment option.
- Review the definitive Underwriting Agreement (Exhibit 1.1) and Warrant (Exhibit 4.1) for specific indemnification and termination clauses.
- Monitor the 90-day lock-up expiration date for potential insider selling pressure.